Indian drugmaker Zydus Cadila said on Thursday it has applied for emergency use approval of its three-dose Covid-19 vaccine that showed efficacy of 66.6% in an interim study and could become the second home-grown shot if regulators consent. Although coronavirus infections have dropped from a devastating peak in April and May that strained healthcare facilities, experts have warned of a third wave, saying widespread vaccination is one of the best pandemic defences.from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/3dznl8j
https://ift.tt/3dwNTXS
0 Comments